Neuren Pharmaceuticals
Home
About Us
Company Overview
Leadership Team
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
Investor Information
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
Contact Us
Email Alerts
Home
>
Contact Us
>
Email Alerts
Font Smaller
Font larger
Print Page
Please enter your email address below to unsubscribe
:
Email
